Published On: 6/11/2024
EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at EASL 2024 titled “A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.”
Focusing on metabolic dysfunction-associated stereotactic liver disease (MASLD), the study investigated disease progression impact on patient-reported outcomes (PROs) and highlights the increased burden on patients as the disease advances. Watch this video presentation by Dr. Sanyal highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
McKinley Peter
Digital Marketing Specialist
+1 (352) 514-8045
More News
-
05/09/2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research -
05/08/2025
EASL 2025 Research: Presentation by Michael Roden, MD -
04/25/2025
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis? -
04/03/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data -
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life